AbGn-107 will be administered every 14 days (Q2W regimen) or 28 days. Update Monoclonal Antibody (mAb) IgG1 AG7 targeting CD71 Linker Cleavable linker Drug/Payload Tubulin inhibitor DM4 Cleavage Mechanism/MOA Immunomodulators Clinical Trials A Study of AbGn-107 in Patients With Gastric, ...
抗HUMAN CD71/TFRC (ABGN-107) 单克隆抗体 CBNumber: CB112783334 分子式: 分子量: 0 MOL File: Mol file 化学性质安全信息用途供应商0 抗HUMAN CD71/TFRC (ABGN-107) 单克隆抗体化学性质 安全信息 抗HUMAN CD71/TFRC (ABGN-107) 单克隆抗体性质、用途与生产工艺 ...